Literature DB >> 10389764

Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72).

N Rochet1, J Dubousset, C Mazeau, E Zanghellini, M F Farges, H S de Novion, A Chompret, B Delpech, N Cattan, M Frenay, J Gioanni.   

Abstract

Permanent human osteosarcoma cell lines are important tools for the study of bone cancer. As representative of an osteoblastic phenotype, they partly reflect their normal osteoblastic counterparts and, thus, may represent appropriate models to investigate the mechanisms involved in bone remodelling and in haematopoietic differentiation. In the present work, we describe a new human cell line, CAL 72, obtained from an osteosarcoma of the knee of a 10-year-old boy. These cells grow in continuous culture, and karyotypic analysis has revealed clonal abnormalities in number and structure, especially loss of chromosome Y. These cells exhibit morphological, immuno-histochemical and molecular characteristics of the osteoblastic lineage. Using RT-PCR, we have shown that the CAL 72 cell line expresses high levels of mRNA coding for several cytokines, such as G-CSF, GM-CSF, IL-1beta and IL-6. In view of this expression profile, the CAL 72 phenotype appears to be closer to normal primary osteoblasts than other reported osteosarcomas. Moreover, these cells express mRNA for both HGF and its receptor c-MET, suggesting that this autocrine loop might contribute to the invasiveness of the tumour from which CAL 72 originated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389764     DOI: 10.1002/(sici)1097-0215(19990719)82:2<282::aid-ijc20>3.0.co;2-r

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  [In vitro trials with single and co-cultures of osteoblasts and endothelial cells : evaluation of new biomaterials for bone reconstruction and regeneration].

Authors:  R E Unger; S Halstenberg; H Günther; A Sartoris; C Brochhausen; C J Kirkpatrick
Journal:  Orthopade       Date:  2009-11       Impact factor: 1.087

2.  In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum.

Authors:  Oystein Bruserud; Karl Johan Tronstad; Rolf Berge
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-18       Impact factor: 4.553

3.  Establishment and characterization of OS 99-1, a cell line derived from a highly aggressive primary human osteosarcoma.

Authors:  Jennifer M Gillette; C Parker Gibbs; Sheila M Nielsen-Preiss
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-02-05       Impact factor: 2.416

4.  Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion.

Authors:  Olivia Fromigué; Zahia Hamidouche; Pierre J Marie
Journal:  J Biol Chem       Date:  2008-08-29       Impact factor: 5.157

5.  Fra-2/AP-1 controls bone formation by regulating osteoblast differentiation and collagen production.

Authors:  Aline Bozec; Latifa Bakiri; Maria Jimenez; Thorsten Schinke; Michael Amling; Erwin F Wagner
Journal:  J Cell Biol       Date:  2010-09-13       Impact factor: 10.539

Review 6.  Tumor evasion from T cell surveillance.

Authors:  Katrin Töpfer; Stefanie Kempe; Nadja Müller; Marc Schmitz; Michael Bachmann; Marc Cartellieri; Gabriele Schackert; Achim Temme
Journal:  J Biomed Biotechnol       Date:  2011-11-15

Review 7.  Origin and Therapies of Osteosarcoma.

Authors:  Brice Moukengue; Morgane Lallier; Louise Marchandet; Marc Baud'huin; Franck Verrecchia; Benjamin Ory; Francois Lamoureux
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

8.  Establishment of a new human osteosarcoma cell line, UTOS-1: cytogenetic characterization by array comparative genomic hybridization.

Authors:  Taketoshi Yasuda; Masahiko Kanamori; Shigeharu Nogami; Takeshi Hori; Takeshi Oya; Kayo Suzuki; Tomoatsu Kimura
Journal:  J Exp Clin Cancer Res       Date:  2009-02-25

9.  Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.

Authors:  J Posthumadeboer; S R Piersma; T V Pham; P W van Egmond; J C Knol; A M Cleton-Jansen; M A van Geer; V W van Beusechem; G J L Kaspers; B J van Royen; C R Jiménez; M N Helder
Journal:  Br J Cancer       Date:  2013-09-24       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.